study design and the pretria1 phasesection
HLA-A*02-eligible and MAGE-A4-eligible patients were enrolled from a multicenter, screening protocol study (NCT02636855). A total of 854 HLA-A*02-eligible patients proceeded to tumor MAGE-A4 testing: 225 were MAGE-A4+. This phase 1 trial used a 3 + 3 design, involving afami-cel ...
The key to our design principle is to decrease the content of V with a low tracer diffusivity in Ti−6Al−4V whilst introducing small amounts of Fe with much higher tracer diffusivity, which enables faster elemental partitioning and thereby encourages in-situ formation of the lamellar (α ...
Study design/Objectives: Study I3Y-MC-JPCP (ClinicalTrials.gov, NCT03703466) was a multicenter, randomized, open-label phase 2 study designed to evaluate... A Stewart - 《Leukemia》 被引量: 0发表: 2007年 Lijekovi i metode Clinical trials Summary. The aim of the study was to determine wh...
On day 29 the patients received a pre-dose infusion of HH1 (50 mg, cold CD37 antibody) followed by the radioimmunoconjugate 177Lu-DOTA-HH1administered as a 10 minute iv bolus. A 3 x 3 dose escalation design was used with 10 MBq/kg as the starting level. Patients were assessed for...
A Microsoft Certified Systems Engineer is trained and certified on a range of Microsoft systems products, including components of the Microsoft BackOffice™. MCSEs understand the interactions and benefits of Windows NT Directory Services, replication issues, and architectural design for multiple network ...
Trial Design This study comprises a dose escalation (step 1) to determine the Dose-Limiting Toxicities, Maximum Tolerated Dose (MTD), and Recommended phase II Dose (RP2Ds) of BI 765063 monotherapy and with BI 754091, and dose-confirmation expansion cohorts (step 2). In Step 1, ascending ...
This first-in-human study investigated the MTD, recommended dose for expansion (RDE), safety, preliminary activity, pharmacokinetics, and pharmacodynamics of ribociclib in patients with Rb+ advanced solid tumors or lymphomas.Experimental Design: Patients received escalating doses of ribociclib (3-...
Study Design and Treatment Prior phase I studies showed that 640 mg of custirsen was the biologically effective dose, that is, the dose at which tumors demonstrated a 92% reduction of CLU mRNA,10 and that custirsen was well tolerated in conjunction with docetaxel chemotherapy.14 Thus, the curre...
The limitations of this study include the single-center design of the phase Ia stage of the study which may reduce the generalizability of the findings, but was implemented to enable optimal safety oversight of the early stages of the trial. In addition, this study only included Chinese patients...